Branden S. Moriarity

This paper develops a base editing platform to efficiently and safely engineer CAR T cells with multiple gene knockouts and insertions.

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

This study develops and tests multiplex-engineered NK cells in rhesus macaques to target HIV reservoirs by enhancing homing to B cell follicles.

This study models CISH-KO TIL therapy in gastrointestinal cancer, finding that T-cell persistence and endogenous competition are key determinants of treatment response.

This paper develops a scalable, non-viral method to engineer and expand polyclonal γδ CAR-T cells, showing their functional efficacy and subset-specific responses in vivo.

The paper develops a mechanistic model to predict the efficacy of CISH knockout in TILs and identifies synergistic gene targets to enhance T cell activation.

This study physically optimizes T cells to enhance their ability to sample and engage with pancreatic ductal adenocarcinoma tumor cells, improving therapeutic outcomes.

This study identifies Noxa's role in metabolic reprogramming to glutamine dependence in CD8+ T cells, independent of its canonical apoptotic function, and suggests its potential as an immunotherapeutic target.

This study evaluates CAR/CXCR5 NK cells in HIV-infected humanized mice, showing improved viral control when administered during viral recrudescence.

This paper uses base editing to introduce dominant-negative mutations in FAS and TGFβR2 in primary T cells, enhancing their anti-tumor efficacy and persistence in solid tumor models.

This paper develops CD38KO/CD38-CAR γδT cells for T cell malignancies, showing they effectively target T-ALL without causing fratricide or GvHD.

This study evaluates CAR/CXCR5-T cell therapy in HIV-infected hDRAGA mice, showing persistence and safety but no viral load reduction due to CAR/T cell HIV infection.

This study enhances CAR-NK cell functionality using non-viral base editing and transposon integration, showing improved therapeutic potential in Burkitt's lymphoma models.

This study shows that deleting CISH enhances T cell anti-cancer functions more than other intracellular checkpoints, improving tumor antigen recognition and killing in CAR-T cells.

This study demonstrates that genetically engineered memory T cells can deliver enzyme replacement therapy for mucopolysaccharidosis type I, reducing GAG levels in multiple tissues for up to 22 weeks.

MultiEditR is a tool that detects and quantifies RNA editing from Sanger sequencing, offering a cost-effective validation method for RNA editing sites.

This study develops a method to efficiently edit multiple genes in human T cells using base editors, reducing off-target effects and improving safety for immunotherapy.

GeneWeld enables efficient and precise targeted integration in multiple species using CRISPR/Cas9 with minimal homology arms.

This paper describes optimized CRISPR/Cas9 genome engineering of primary human B cells, achieving high-efficiency gene knockout and site-specific integration.

EditR quantifies base editing efficiency from Sanger sequencing data, offering accuracy and cost-effectiveness compared to existing methods.